DE69833509T2 - Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation - Google Patents

Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation Download PDF

Info

Publication number
DE69833509T2
DE69833509T2 DE69833509T DE69833509T DE69833509T2 DE 69833509 T2 DE69833509 T2 DE 69833509T2 DE 69833509 T DE69833509 T DE 69833509T DE 69833509 T DE69833509 T DE 69833509T DE 69833509 T2 DE69833509 T2 DE 69833509T2
Authority
DE
Germany
Prior art keywords
alkyl
oder
aryl
und
ist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833509T
Other languages
German (de)
English (en)
Other versions
DE69833509D1 (de
Inventor
R. Walter Pompton Plains BISHOP
J. Joseph Guilford CATINO
J. Ronald Maplewood DOLL
Ashit Upper Montclair GANGULY
Viyyoor Parsippany GIRIJAVALLABHAN
Paul Basking Ridge KIRSCHMEIER
Ming Fanwood LIU
L. Loretta Millington NIELSEN
L. David Moorestown CUTLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69833509(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69833509D1 publication Critical patent/DE69833509D1/de
Publication of DE69833509T2 publication Critical patent/DE69833509T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69833509T 1997-12-22 1998-12-21 Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation Expired - Lifetime DE69833509T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US143529 1998-08-28
US18196998A 1998-10-29 1998-10-29
US181969 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
US996027 2004-11-23

Publications (2)

Publication Number Publication Date
DE69833509D1 DE69833509D1 (de) 2006-04-20
DE69833509T2 true DE69833509T2 (de) 2006-10-26

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833509T Expired - Lifetime DE69833509T2 (de) 1997-12-22 1998-12-21 Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation

Country Status (25)

Country Link
EP (1) EP1041985B1 (enExample)
JP (1) JP4502503B2 (enExample)
KR (1) KR100700907B1 (enExample)
CN (1) CN1129431C (enExample)
AR (1) AR017440A1 (enExample)
AT (1) ATE317697T1 (enExample)
AU (1) AU756762B2 (enExample)
BR (1) BR9814419A (enExample)
CA (1) CA2315693C (enExample)
CL (1) CL2007001889A1 (enExample)
CO (1) CO5080764A1 (enExample)
CZ (1) CZ298511B6 (enExample)
DE (1) DE69833509T2 (enExample)
DK (1) DK1041985T3 (enExample)
ES (1) ES2255196T3 (enExample)
HU (1) HUP0102473A3 (enExample)
IL (1) IL136462A0 (enExample)
MY (1) MY137303A (enExample)
NO (1) NO326832B1 (enExample)
NZ (1) NZ504928A (enExample)
PE (1) PE20000042A1 (enExample)
PT (1) PT1041985E (enExample)
SK (1) SK285584B6 (enExample)
TW (1) TW581763B (enExample)
WO (1) WO1999032114A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
RU2298417C2 (ru) * 1999-11-09 2007-05-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Продукт, включающий ингибитор трансдукции сигналов гетеротримерных протеинов g в комбинации с другим цитостатическим средством, для терапевтического применения при лечении рака
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
JP2003525237A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064198A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064195A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
AU2001235496A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
WO2001064196A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
BR0214564A (pt) * 2001-11-30 2004-11-09 Schering Corp Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
CA2468996A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
EP0856315B1 (en) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids
DE69635424T2 (de) * 1995-12-22 2006-08-03 Schering Corp. Zur hemming der g-protein-funktion und zur behandlung proliferativer krankheiten geeignete tricyclische amide
ATE314843T1 (de) * 1996-03-12 2006-02-15 Pg Txl Co Lp Wasserlösliche paclitaxel-prodrogen
JP2000507584A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US20020034725A1 (en) * 1996-04-15 2002-03-21 W. Gillies Mckenna Sensitization of cells to radiation and and chemotherapy
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
DE69734785T2 (de) * 1997-01-29 2006-08-03 Picker Medical Systems, Ltd. Vorherbestimmung zur verfolgung der optimalen kontrastmittelkonzentration
SK285969B6 (sk) * 1997-02-18 2007-12-06 Canji, Inc. Prípravky na liečenie cicavčích nádorových alebo hyperproliferatívnych buniek

Also Published As

Publication number Publication date
HUP0102473A2 (hu) 2002-01-28
NO20003229L (no) 2000-08-22
CZ298511B6 (cs) 2007-10-24
CO5080764A1 (es) 2001-09-25
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
SK8982000A3 (en) 2001-04-09
EP1041985B1 (en) 2006-02-15
KR100700907B1 (ko) 2007-03-29
PT1041985E (pt) 2006-07-31
NO326832B1 (no) 2009-02-23
AU1907299A (en) 1999-07-12
MY137303A (en) 2009-01-30
EP1041985A1 (en) 2000-10-11
CN1284875A (zh) 2001-02-21
PE20000042A1 (es) 2000-02-17
JP2001526224A (ja) 2001-12-18
CZ20002236A3 (cs) 2001-04-11
ES2255196T3 (es) 2006-06-16
KR20010033452A (ko) 2001-04-25
JP4502503B2 (ja) 2010-07-14
DK1041985T3 (da) 2006-06-19
AU756762B2 (en) 2003-01-23
TW581763B (en) 2004-04-01
NO20003229D0 (no) 2000-06-21
IL136462A0 (en) 2001-06-14
CL2007001889A1 (es) 2008-01-11
ATE317697T1 (de) 2006-03-15
CN1129431C (zh) 2003-12-03
AR017440A1 (es) 2001-09-05
WO1999032114A1 (en) 1999-07-01
HUP0102473A3 (en) 2003-07-28
NZ504928A (en) 2004-12-24
SK285584B6 (sk) 2007-04-05
DE69833509D1 (de) 2006-04-20
CA2315693C (en) 2010-11-30

Similar Documents

Publication Publication Date Title
DE60032226T2 (de) Verfahren zur induktion von krebszellentod und tumorregression
DE69833509T2 (de) Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation
US6333333B1 (en) Methods for treating proliferative diseases
DE69625518T2 (de) Wirkstoff zur behandlung neurodegenerativer störungen
DE19542281C2 (de) Verwendung von Epinastin für die Behandlung der Migräne
DE19814838C2 (de) Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE60216139T3 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
DE69535234T2 (de) Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
DE60130017T2 (de) Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
DE69017302T2 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE60214846T2 (de) Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit
DE69628645T2 (de) Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums
WO2002020521A1 (de) Verwendung von indolderivaten zur behandlung von erkrankungen des zentralen nervensystems
DE68923151T2 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
DE19953414A1 (de) Imidazopyridinderivate als Phospodiesterase VII-Hemmer
DE69531722T2 (de) Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
DE69623555T2 (de) Inhibitor der krebsmetastasierung
DE68907392T2 (de) Dysmnesie modifizierende Arzneimittel.
EP0859613B1 (de) Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
DE602004011781T2 (de) Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen
DE69919789T2 (de) Loratadin zur Verwendung als Antiarrhythmikum
DE60318561T2 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
DE2401446A1 (de) Pharmazeutische zubereitungen zur linderung von hautproliferationserkrankungen
DE3930282A1 (de) Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition